Skip to main content

PsA/SpA

Podcast microphone headphones
Day 1 (part two): ACR 2019 Podcast
RheumNow
Podcast microphone headphones
Podcast microphone headphones
Day 4: ACR 2019 Podcast
RheumNow
Podcast microphone headphones
Day 2 (part two) ACR 2019 Podcast
RheumNow
Podcast microphone headphones
Day 2 (part one) Podcast
RheumNow
Podcast microphone headphones
Panel Presentation: Psoriatic Arthritis

Drs. Eric Ruderman, Alexis Ogdie, Jessica Walsh, and Jose Scher discuss the giselkumab trials, where IL-23 inhibitors fit in practice, ixekizumab withdrawal, and more that presented at the 2019 ACR/ARP annual meeting in Atlanta. 

Pearls for Evaluating PSA patients: Dr. Guillermo Valenzuela

Dr. Valenzuela describes a variety of pearls for evaluating PSA patients at the 2019 ACR/ARP annual meeting in Atlanta. 

#ACR19 Rheumatology RoundUp - Kavanaughs Picks: 2505 PsA prevention1366 Self Joint exams1120 Rheum burnout1310 OA Hx565 Enteropathic arthritis Re

Dr. John Cush RheumNow

6 months 2 weeks ago

#ACR19 Rheumatology RoundUp - Kavanaughs Picks: 2505 PsA prevention 1366 Self Joint exams 1120 Rheum burnout 1310 OA Hx 565 Enteropathic arthritis Recs 1823 MRE dx of SI 2773 Machine learning 2772 Antiinflammatory diet in RA 1359 Synovial Bx

Tofacitinib as Monotherapy Following MTX Withdrawal in PsA: Dr. Eric Ruderman

Dr. Ruderman describes abstract #L14 presented at the 2019 ACR/ARP annual meeting in Atlanta. 

RT @Janetbirdope: Killed zoster vaccine was safe with no flare of RA and PsA We need to know if response was good. #ACR19 @RheumNow abst2…

Janet Pope Janetbirdope

6 months 2 weeks ago

Killed zoster vaccine was safe with no flare of RA and PsA We need to know if response was good. #ACR19 @RheumNow abst2093 https://t.co/xp2Ju5wZWK

Ixekizimab Withdrawal in PSA: Dr. Eric Ruderman

Dr. Ruderman highlights abstract #1532 at the 2019 ACR/ARP annual meeting in Atlanta.

Comparison of Ixekizumab and Adalimumab in PsA: Dr. Olga Petryna

Dr. Petryna discusses abstract #L20 presented at the 2019 ACR/ARP annual meeting in Atlanta. 

RT @Janetbirdope: 1/3 of pts using apremilast with PsA/SpA from Corrona data base are using it in combination with bDMARDs. Not sure how th…

Janet Pope Janetbirdope

6 months 2 weeks ago

1/3 of pts using apremilast with PsA/SpA from Corrona data base are using it in combination with bDMARDs. Not sure how they get reimbursement #ACR #ACR19 #psoriaticarthritis @RheumNow abstract 1481

RT @uptoTate: MAXIMISE results in axial manifestations of PsA. SEC met primary phase 3b ASAS 20 endpoint after inadequate NSAID response. h…

Dr. Rachel Tate uptoTate

6 months 2 weeks ago

MAXIMISE results in axial manifestations of PsA. SEC met primary phase 3b ASAS 20 endpoint after inadequate NSAID response. https://t.co/e1j03KOo1K #ACR19 @RheumNow abs#2880 https://t.co/UtSDJGAW2G

RT @uptoTate: Phase 2b Bimekizumab study results in PsA shows neutralizing IL 17F and IL 17A may be a new target for LDA/treatment. https:…

Dr. Rachel Tate uptoTate

6 months 2 weeks ago

Phase 2b Bimekizumab study results in PsA shows neutralizing IL 17F and IL 17A may be a new target for LDA/treatment. https://t.co/uHvkFJn5z7 #ACR19 @RheumNow abs#2881 https://t.co/2EfzmyxY4M

RT @uptoTate: Risankizumab (RZB), humanized IgG1 monoclonal antibody and selective IL23p19 inhibitor, superior to PBO in PsA. Initial phase…

Dr. Rachel Tate uptoTate

6 months 2 weeks ago

Risankizumab (RZB), humanized IgG1 monoclonal antibody and selective IL23p19 inhibitor, superior to PBO in PsA. Initial phase 2 results. No new safety signals noted. https://t.co/Jv1zpcg5Zd #ACR19 @RheumNow abs#2877

RT @Janetbirdope: Tofa is not different from bDMARDs in Corrona for cancer and deaths. reassuring and adds to growing safety data #ACR #ACR…

Janet Pope Janetbirdope

6 months 2 weeks ago

Tofa is not different from bDMARDs in Corrona for cancer and deaths. reassuring and adds to growing safety data #ACR #ACR19 @RheumNow abstr 2874 https://t.co/pLVAkQ7UR6

RT @uptoTate: Go-DACT proof on concept results: golimumab + MTX superior to monotherapy MTX in PsA dactylitis. https://t.co/dEGnjiuGZf #ACR…

Dr. Rachel Tate uptoTate

6 months 2 weeks ago

Go-DACT proof on concept results: golimumab + MTX superior to monotherapy MTX in PsA dactylitis. https://t.co/dEGnjiuGZf #ACR19 @RheumNow abs#2876

×